abrocitinib vs LW402
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK1 · full Atopic Dermatitis pipeline
abrocitinib · Cibinqo
Marketed by Pfizer
NCT03349060 · Phase 3 · completed
A randomized, quadruple-blind, placebo-controlled phase 3 trial enrolling 387 participants with moderate-to-severe atopic dermatitis. The co-primary endpoints (IGA response and EASI-75 at week 12) were both statistically significant for the 100 mg and 200 mg doses versus placebo, with large absolute differences (e.g. 43.8% vs 7.9% for IGA). The adequate sample size, blinded design, and positive hard clinical endpoints justify the strong evidence grade.
Next expected readout: May 2027 · NCT07848074 (registry estimate)
Reported efficacy
Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2; Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 4: Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 (Week 2): Abrocitinib 200 mg QD 48.2% (95% CI 43 to 53.4) vs Dupilumab 300 mg Q2W 25.5% (95% CI 21.1 to 30) (met)
Result source: NCT04345367
LW402
Developed by Shanghai Longwood Biopharmaceuticals
NCT07186387 · Phase 2 · completed
The trial was randomized and quadruple-blind, used a placebo control, and enrolled 144 participants; its primary endpoint was a clinical disease-response measure (EASI-50). Because the primary comparison result is not available, the study provides well-designed but incomplete evidence rather than evidence of a confirmed favorable effect.
Next expected readout: March 2028 · NCT07370909 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | abrocitinib | LW402 |
|---|---|---|
| EASI-75 | 39.7% vs 11.8%+27.9 vs placeboNCT0334906094 other results
| —Trial running · NCT07370909 |
| IGA 0/1 with 2-point improvement | 27.8% vs 6.3%+21.5 vs placeboNCT0278016735 other results
| —Trial running · NCT07370909 |
| EASI-90 | 28.5% vs 14.6%vs DupilumabNCT0434536794 other results
| —Trial running · NCT07370909 |
| EASI, % change | -60% vs -28.6%−31.4 vs placeboNCT0357587151 other results
| —Trial running · NCT07370909 |
EASI-75
- abrocitinib
- 39.7% vs 11.8%+27.9 vs placeboNCT03349060
94 other results
- 44.5% vs 10.4% NCT03575871
- 58.7% vs 27.1% NCT03720470
- 68.5% vs 41.5% NCT03796676
- 62.7% vs 11.8% NCT03349060
- 61% vs 10.4% NCT03575871
- 70.3% vs 27.1% NCT03720470
- 72% vs 41.5% NCT03796676
- 46.5% vs 14% NCT03627767
- 54.2% vs 15.1% NCT03627767
- 60.4% vs 18% NCT03627767
- 60.3% vs 30.6% NCT03720470
- 76% vs 27% NCT03627767
- 100% vs 99.2% NCT03627767
- 38.3% vs 13.3% NCT03349060
- 43.3% vs 12.8% NCT03575871
- 55.6% vs 18.6% NCT03720470
- 60.4% vs 33.3% NCT03796676
- 27.6% vs 14.5% NCT03349060
- 26.5% vs 6.5% NCT03575871
- 44.6% vs 15.6% NCT03720470
- 41.3% vs 14.6% NCT03796676
- 10.3% vs 3.9% NCT03349060
- 10.2% vs 1.3% NCT03575871
- 25.4% vs 10.9% NCT03720470
- 19.6% vs 4.4% NCT03796676
- 65.8% vs 14% NCT03627767
- 71.8% vs 15.1% NCT03627767
- 80.5% vs 18% NCT03627767
- 71% vs 30.6% NCT03720470
- 92.5% vs 27% NCT03627767
- 99.6% vs 99.2% NCT03627767
- 57.8% vs 13.3% NCT03349060
- 60.4% vs 12.8% NCT03575871
- 67.9% vs 18.6% NCT03720470
- 68.5% vs 33.3% NCT03796676
- 47.4% vs 14.5% NCT03349060
- 51% vs 6.5% NCT03575871
- 57.4% vs 15.6% NCT03720470
- 63.8% vs 14.6% NCT03796676
- 24% vs 3.9% NCT03349060
- 24.3% vs 1.3% NCT03575871
- 30% vs 10.9% NCT03720470
- 25.5% vs 4.4% NCT03796676
- 73% vs 72.3% NCT04345367
- 76.1% vs 71.1% NCT04345367
- 77.3% vs 67.8% NCT04345367
- 76.3% vs 61.4% NCT04345367
- 71% vs 52.8% NCT04345367
- 57.6% vs 36.8% NCT04345367
- 29.4% vs 21.3% NCT04345367
- 25% vs 32.1% NCT02780167
- 35% vs 31.3% NCT02780167
- 36.8% vs 26.7% NCT02780167
- 40.7% vs 15.4% NCT02780167
- 40% vs 20% NCT02780167
- 38.2% vs 16.4% NCT02780167
- 27.3% vs 10.9% NCT02780167
- 12.7% vs 5.5% NCT02780167
- 3.6% vs 3.7% NCT02780167
- 36.8% vs 32.1% NCT02780167
- 45.5% vs 31.3% NCT02780167
- 55.6% vs 26.7% NCT02780167
- 64.6% vs 15.4% NCT02780167
- 73.6% vs 20% NCT02780167
- 68.5% vs 16.4% NCT02780167
- 57.4% vs 10.9% NCT02780167
- 36.5% vs 5.5% NCT02780167
- 16.7% vs 3.7% NCT02780167
- 3.7% vs 32.1% NCT02780167
- 6.9% vs 31.3% NCT02780167
- 12.9% vs 26.7% NCT02780167
- 13.3% vs 15.4% NCT02780167
- 22% vs 20% NCT02780167
- 18% vs 16.4% NCT02780167
- 20% vs 10.9% NCT02780167
- 6% vs 5.5% NCT02780167
- 6% vs 3.7% NCT02780167
- 38.5% vs 32.1% NCT02780167
- 25% vs 31.3% NCT02780167
- 27.6% vs 26.7% NCT02780167
- 17.4% vs 15.4% NCT02780167
- 22.4% vs 20% NCT02780167
- 18.4% vs 16.4% NCT02780167
- 18.4% vs 10.9% NCT02780167
- 12.2% vs 5.5% NCT02780167
- 2.1% vs 3.7% NCT02780167
- 43.8% vs 0% NCT03915496
- 46.7% vs 0% NCT03915496
- 46.7% vs 0% NCT03915496
- 6.3% vs 0% NCT03915496
- 78.6% vs 0% NCT03915496
- 78.6% vs 0% NCT03915496
- 50% vs 0% NCT03915496
- 38.5% vs 0% NCT03915496
- LW402
- —Trial running · NCT07370909
IGA 0/1 with 2-point improvement
- abrocitinib
- 27.8% vs 6.3%+21.5 vs placeboNCT02780167
35 other results
- 44.5% vs 6.3% NCT02780167
- 12.3% vs 6.3% NCT02780167
- 8.2% vs 6.3% NCT02780167
- 13.9% vs 10.7% NCT02780167
- 12.5% vs 18.8% NCT02780167
- 23.7% vs 10% NCT02780167
- 16.4% vs 5.5% NCT02780167
- 12.7% vs 14.5% NCT02780167
- 16.4% vs 1.8% NCT02780167
- 3.6% vs 3.6% NCT02780167
- 1.8% vs 0% NCT02780167
- 18.4% vs 10.7% NCT02780167
- 15.9% vs 18.8% NCT02780167
- 26.7% vs 10% NCT02780167
- 41.5% vs 5.5% NCT02780167
- 40.7% vs 14.5% NCT02780167
- 40.7% vs 1.8% NCT02780167
- 11.5% vs 3.6% NCT02780167
- 3.7% vs 0% NCT02780167
- 7.4% vs 10.7% NCT02780167
- 3.4% vs 18.8% NCT02780167
- 12.9% vs 10% NCT02780167
- 12% vs 5.5% NCT02780167
- 14% vs 14.5% NCT02780167
- 8% vs 1.8% NCT02780167
- 6% vs 3.6% NCT02780167
- 2% vs 0% NCT02780167
- 23.1% vs 10.7% NCT02780167
- 10.7% vs 18.8% NCT02780167
- 20.7% vs 10% NCT02780167
- 8.2% vs 5.5% NCT02780167
- 14.3% vs 14.5% NCT02780167
- 8.2% vs 1.8% NCT02780167
- 6.1% vs 3.6% NCT02780167
- 2.1% vs 0% NCT02780167
- LW402
- —Trial running · NCT07370909
EASI-90
- abrocitinib
- 28.5% vs 14.6%vs DupilumabNCT04345367
94 other results
- 37.6% vs 10.6% NCT03627767
- 41.5% vs 12.1% NCT03627767
- 46.9% vs 10.5% NCT03627767
- 38% vs 11.3% NCT03720470
- 51.3% vs 13.9% NCT03627767
- 18.6% vs 5.3% NCT03349060
- 23.9% vs 3.9% NCT03575871
- 36.6% vs 10.1% NCT03720470
- 41.6% vs 18.1% NCT03796676
- 87.1% vs 84.6% NCT03627767
- 14.3% vs 5.3% NCT03349060
- 17.2% vs 2.6% NCT03575871
- 30.6% vs 7.8% NCT03720470
- 29.7% vs 14% NCT03796676
- 7.9% vs 3.9% NCT03349060
- 9.7% vs 0% NCT03575871
- 20.2% vs 6.3% NCT03720470
- 17.4% vs 2.1% NCT03796676
- 1.9% vs 1.3% NCT03349060
- 2.5% vs 0% NCT03575871
- 8.3% vs 2.3% NCT03720470
- 8.7% vs 0% NCT03796676
- 54.5% vs 10.6% NCT03627767
- 58.7% vs 12.1% NCT03627767
- 64.5% vs 10.5% NCT03627767
- 48.9% vs 11.3% NCT03720470
- 77.1% vs 13.9% NCT03627767
- 38.6% vs 5.3% NCT03349060
- 37.7% vs 3.9% NCT03575871
- 46.1% vs 10.1% NCT03720470
- 49.5% vs 18.1% NCT03796676
- 86.4% vs 84.6% NCT03627767
- 33.1% vs 5.3% NCT03349060
- 34.4% vs 2.6% NCT03575871
- 47.3% vs 7.8% NCT03720470
- 40.2% vs 14% NCT03796676
- 24.3% vs 3.9% NCT03349060
- 22.9% vs 0% NCT03575871
- 32.3% vs 6.3% NCT03720470
- 30.9% vs 2.1% NCT03796676
- 5.2% vs 1.3% NCT03349060
- 9.2% vs 0% NCT03575871
- 11.2% vs 2.3% NCT03720470
- 10.6% vs 0% NCT03796676
- 54.6% vs 47.6% NCT04345367
- 58.4% vs 45.7% NCT04345367
- 54.3% vs 41.9% NCT04345367
- 47.6% vs 33.6% NCT04345367
- 45.4% vs 25.4% NCT04345367
- 11.6% vs 7.2% NCT04345367
- 8.3% vs 14.3% NCT02780167
- 17.5% vs 15.6% NCT02780167
- 23.7% vs 10% NCT02780167
- 25.9% vs 9.6% NCT02780167
- 23.6% vs 5.5% NCT02780167
- 16.4% vs 7.3% NCT02780167
- 10.9% vs 1.8% NCT02780167
- 5.5% vs 0% NCT02780167
- 0% vs 0% NCT02780167
- 10.5% vs 14.3% NCT02780167
- 18.2% vs 15.6% NCT02780167
- 31.1% vs 10% NCT02780167
- 52.1% vs 9.6% NCT02780167
- 43.4% vs 5.5% NCT02780167
- 44.4% vs 7.3% NCT02780167
- 38.9% vs 1.8% NCT02780167
- 19.2% vs 0% NCT02780167
- 7.4% vs 0% NCT02780167
- 3.7% vs 14.3% NCT02780167
- 0% vs 15.6% NCT02780167
- 3.2% vs 10% NCT02780167
- 0% vs 9.6% NCT02780167
- 8% vs 5.5% NCT02780167
- 14% vs 7.3% NCT02780167
- 8% vs 1.8% NCT02780167
- 4% vs 0% NCT02780167
- 4% vs 0% NCT02780167
- 23.1% vs 14.3% NCT02780167
- 14.3% vs 15.6% NCT02780167
- 13.8% vs 10% NCT02780167
- 10.9% vs 9.6% NCT02780167
- 12.2% vs 5.5% NCT02780167
- 14.3% vs 7.3% NCT02780167
- 8.2% vs 1.8% NCT02780167
- 6.1% vs 0% NCT02780167
- 2.1% vs 0% NCT02780167
- 37.5% vs 0% NCT03915496
- 20% vs 0% NCT03915496
- 20% vs 0% NCT03915496
- 0% vs 0% NCT03915496
- 50% vs 0% NCT03915496
- 57.1% vs 0% NCT03915496
- 28.6% vs 0% NCT03915496
- 0% vs 0% NCT03915496
- LW402
- —Trial running · NCT07370909
EASI, % change
- abrocitinib
- -60% vs -28.6%−31.4 vs placeboNCT03575871
51 other results
- -77.3% vs -63.7% NCT03796676
- -59.5% vs -33% NCT03575871
- -72.6% vs -57.6% NCT03796676
- -54.3% vs -24.4% NCT03575871
- -66.1% vs -41.7% NCT03796676
- -39.2% vs -9% NCT03575871
- -51.5% vs -27.6% NCT03796676
- -73.3% vs -28.6% NCT03575871
- -80.6% vs -63.7% NCT03796676
- -73.2% vs -33% NCT03575871
- -77.8% vs -57.6% NCT03796676
- -69% vs -24.4% NCT03575871
- -74.3% vs -41.7% NCT03796676
- -51.3% vs -9% NCT03575871
- -54.5% vs -27.6% NCT03796676
- -27.7% vs -35.9% NCT02780167
- -38.8% vs -35.5% NCT02780167
- -51.2% vs -29.8% NCT02780167
- -59.0% vs -35.2% NCT02780167
- -54.0% vs -36.7% NCT02780167
- -54.2% vs -39.2% NCT02780167
- -53.6% vs -24.6% NCT02780167
- -38.3% vs -23.5% NCT02780167
- -19.9% vs -12.3% NCT02780167
- -55.8% vs -35.9% NCT02780167
- -57.1% vs -35.5% NCT02780167
- -66.3% vs -29.8% NCT02780167
- -82.6% vs -35.2% NCT02780167
- -84.5% vs -36.7% NCT02780167
- -83.1% vs -39.2% NCT02780167
- -78.2% vs -24.6% NCT02780167
- -63.3% vs -23.5% NCT02780167
- -41.3% vs -12.3% NCT02780167
- -20.8% vs -35.9% NCT02780167
- -26.3% vs -35.5% NCT02780167
- -33.0% vs -29.8% NCT02780167
- -40.7% vs -35.2% NCT02780167
- -36.8% vs -36.7% NCT02780167
- -40.2% vs -39.2% NCT02780167
- -32.8% vs -24.6% NCT02780167
- -26.3% vs -23.5% NCT02780167
- -14.8% vs -12.3% NCT02780167
- -45.2% vs -35.9% NCT02780167
- -31.5% vs -35.5% NCT02780167
- -34.1% vs -29.8% NCT02780167
- -31.1% vs -35.2% NCT02780167
- -39.4% vs -36.7% NCT02780167
- -35.2% vs -39.2% NCT02780167
- -30.1% vs -24.6% NCT02780167
- -14.8% vs -23.5% NCT02780167
- -13.8% vs -12.3% NCT02780167
- LW402
- —Trial running · NCT07370909
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
LW402: no structured comparison results are available for Atopic Dermatitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. abrocitinib: 4 of 4 rows · LW402: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | abrocitinib |
|---|---|
| Dropout rate | 13.5%100 mga NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 24 more results11%200 mg NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 9.7%200 mg QD NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 13.3%100 mg NCT03575871 · Phase 3 9%200 mg NCT03575871 · Phase 3 —100 mg NCT03720470 · Phase 3 8.8%100 mg NCT03720470 · Phase 3 —200 mg NCT03720470 · Phase 3 8%200 mg NCT03720470 · Phase 3 3.2%100mg QD NCT03796676 · Phase 3 3.2%200mg QD NCT03796676 · Phase 3 6.9%100 mg QD NCT05375929 · Phase 3 · registry result, not featured evidence —100 mg NCT05375929 · Phase 3 · registry result, not featured evidence 8.1%200 mg QD NCT05375929 · Phase 3 · registry result, not featured evidence —200 mg NCT05375929 · Phase 3 · registry result, not featured evidence —100 mg NCT03627767 · Phase 3 · registry result, not featured evidence 35.4%200 mg NCT03627767 · Phase 3 · registry result, not featured evidence —200 mg NCT03627767 · Phase 3 · registry result, not featured evidence —200 mg NCT03627767 · Phase 3 · registry result, not featured evidence 12.5%100 mg QD NCT03915496 · Phase 2 · registry result, not featured evidence 7.1%200 mg QD NCT03915496 · Phase 2 · registry result, not featured evidence 33.9%100mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 30.9%200mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 47.1%30mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 44.9%10mg QD NCT02780167 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 5.8%100 mga NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 24 more results5.8%200 mg NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 3%200 mg QD NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 3.2%100 mg NCT03575871 · Phase 3 3.2%200 mg NCT03575871 · Phase 3 —100 mg NCT03720470 · Phase 3 2.5%100 mg NCT03720470 · Phase 3 —200 mg NCT03720470 · Phase 3 4%200 mg NCT03720470 · Phase 3 1.1%100mg QD NCT03796676 · Phase 3 2.1%200mg QD NCT03796676 · Phase 3 0%100 mg QD NCT05375929 · Phase 3 · registry result, not featured evidence —100 mg NCT05375929 · Phase 3 · registry result, not featured evidence 1%200 mg QD NCT05375929 · Phase 3 · registry result, not featured evidence —200 mg NCT05375929 · Phase 3 · registry result, not featured evidence —100 mg NCT03627767 · Phase 3 · registry result, not featured evidence 4%200 mg NCT03627767 · Phase 3 · registry result, not featured evidence —200 mg NCT03627767 · Phase 3 · registry result, not featured evidence —200 mg NCT03627767 · Phase 3 · registry result, not featured evidence 12.5%100 mg QD NCT03915496 · Phase 2 · registry result, not featured evidence 7.1%200 mg QD NCT03915496 · Phase 2 · registry result, not featured evidence 21.4%100mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 14.5%200mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 15.7%30mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 16.3%10mg QD NCT02780167 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 3.2%100 mga NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 24 more results3.2%200 mg NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.7%200 mg QD NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 3.2%100 mg NCT03575871 · Phase 3 1.3%200 mg NCT03575871 · Phase 3 2.5%100 mg NCT03720470 · Phase 3 0.5%100 mg NCT03720470 · Phase 3 0.9%200 mg NCT03720470 · Phase 3 0%200 mg NCT03720470 · Phase 3 0%100mg QD NCT03796676 · Phase 3 1.1%200mg QD NCT03796676 · Phase 3 1%100 mg QD NCT05375929 · Phase 3 · registry result, not featured evidence 0%100 mg NCT05375929 · Phase 3 · registry result, not featured evidence 0%200 mg QD NCT05375929 · Phase 3 · registry result, not featured evidence 0%200 mg NCT05375929 · Phase 3 · registry result, not featured evidence 3.4%100 mg NCT03627767 · Phase 3 · registry result, not featured evidence 1.6%200 mg NCT03627767 · Phase 3 · registry result, not featured evidence 5.3%200 mg NCT03627767 · Phase 3 · registry result, not featured evidence 1.1%200 mg NCT03627767 · Phase 3 · registry result, not featured evidence 0%100 mg QD NCT03915496 · Phase 2 · registry result, not featured evidence 0%200 mg QD NCT03915496 · Phase 2 · registry result, not featured evidence 5.4%100mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 3.6%200mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 0%30mg QD NCT02780167 · Phase 2 · registry result, not featured evidence 4.1%10mg QD NCT02780167 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 100 mga nasopharyngitis 14.7% (placebo 10.4%) dermatitis atopic 14.1% (placebo 16.9%) nausea 9% (placebo 2.6%) NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 24 more results200 mg nausea 20.1% (placebo 2.6%) nasopharyngitis 11.7% (placebo 10.4%) headache 9.7% (placebo 2.6%) NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 200 mg QD nausea 19.3% headache 13% acne 12.7% NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 100 mg nasopharyngitis 12.7% (placebo 6.4%) upper respiratory tract infection 8.9% (placebo 3.8%) nausea 7.6% (placebo 2.6%) NCT03575871 · Phase 3 200 mg nausea 14.2% (placebo 2.6%) headache 7.7% (placebo 2.6%) nasopharyngitis 7.7% (placebo 6.4%) NCT03575871 · Phase 3 100 mg nasopharyngitis 9.2% (placebo 6.9%) upper respiratory tract infection 5% (placebo 4.6%) headache 4.2% (placebo 4.6%) NCT03720470 · Phase 3 100 mg upper respiratory tract infection 2.8% (placebo 4.6%) cough 1.4% (placebo 1.5%) diarrhoea 1.4% (placebo 3.1%) NCT03720470 · Phase 3 200 mg nausea 11.1% (placebo 1.5%) acne 6.6% (placebo 0%) headache 6.6% (placebo 4.6%) NCT03720470 · Phase 3 200 mg nasopharyngitis 4.3% (placebo 6.9%) upper respiratory tract infection 2.4% (placebo 4.6%) dermatitis atopic 1.9% (placebo 3.1%) NCT03720470 · Phase 3 100mg QD upper respiratory tract infection 9.5% (placebo 10.4%) nasopharyngitis 8.4% (placebo 9.4%) folliculitis 7.4% (placebo 1%) NCT03796676 · Phase 3 200mg QD nausea 18.1% (placebo 1%) upper respiratory tract infection 10.6% (placebo 10.4%) headache 8.5% (placebo 7.3%) NCT03796676 · Phase 3 100 mg QD nausea 5% dermatitis atopic 4% alanine aminotransferase increased 3% NCT05375929 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 10.5% nausea 10.5% cough 5.3% NCT05375929 · Phase 3 · registry result, not featured evidence 200 mg QD nausea 9.1% gastrooesophageal reflux disease 4% pruritus 4% NCT05375929 · Phase 3 · registry result, not featured evidence 200 mg dermatitis atopic 12.5% pyrexia 12.5% asthma 6.3% NCT05375929 · Phase 3 · registry result, not featured evidence 100 mg dermatitis atopic 21.1% (placebo 33%) nausea 13.2% (placebo 16.5%) nasopharyngitis 10.2% (placebo 9.7%) NCT03627767 · Phase 3 · registry result, not featured evidence 200 mg nausea 16.1% (placebo 16.5%) headache 9.7% (placebo 11.6%) nasopharyngitis 6.2% (placebo 9.7%) NCT03627767 · Phase 3 · registry result, not featured evidence 200 mg nausea 18.4% (placebo 16.5%) dermatitis atopic 13.5% (placebo 33%) acne 11.7% (placebo 7.1%) NCT03627767 · Phase 3 · registry result, not featured evidence 200 mg upper respiratory tract infection 6% (placebo 9.7%) nasopharyngitis 4.8% (placebo 9.7%) dermatitis atopic 3.7% (placebo 33%) NCT03627767 · Phase 3 · registry result, not featured evidence 100 mg QD nausea 18.8% (placebo 6.3%) dizziness 12.5% (placebo 0%) abdominal discomfort 6.3% (placebo 0%) NCT03915496 · Phase 2 · registry result, not featured evidence 200 mg QD nausea 28.6% (placebo 6.3%) headache 14.3% (placebo 0%) abdominal distension 7.1% (placebo 0%) NCT03915496 · Phase 2 · registry result, not featured evidence 100mg QD viral upper respiratory tract infection 17.9% (placebo 8.9%) dermatitis atopic 12.5% (placebo 10.7%) headache 8.9% (placebo 3.6%) NCT02780167 · Phase 2 · registry result, not featured evidence 200mg QD nausea 14.5% (placebo 1.8%) dermatitis atopic 12.7% (placebo 10.7%) viral upper respiratory tract infection 12.7% (placebo 8.9%) NCT02780167 · Phase 2 · registry result, not featured evidence 30mg QD dermatitis atopic 17.6% (placebo 10.7%) viral upper respiratory tract infection 11.8% (placebo 8.9%) headache 9.8% (placebo 3.6%) NCT02780167 · Phase 2 · registry result, not featured evidence 10mg QD dermatitis atopic 16.3% (placebo 10.7%) viral upper respiratory tract infection 10.2% (placebo 8.9%) diarrhoea 6.1% (placebo 1.8%) NCT02780167 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 22 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
abrocitinib
show 40 more results
show 94 more results
show 31 more results
show 55 more results
show 2 more results
show 15 more results
show 87 more results
show 94 more results
show 43 more results
show 7 more results
show 94 more results
show 17 more results
+ 129 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: abrocitinib's landscape · LW402's landscape